I can't speak to what happened at the clinical trial site that DND was supervising. The information I have is that Health Canada approved the trial. The trial was submitted by the manufacturer, Hoffmann-La Roche, and as part of that trial there was a protocol, there was an informed consent document, and there was responsibility on the part of the manufacturer or sponsor of the trial to carry out the trial in the manner described in the protocol, which included informed consent.
Given the experience in Europe and in the U.S., because the product was already market-authorized there, there was already an understanding that there was potentially a problem if you had neuropsychiatric problems. The information that would have been available from those product monographs, I assume, would have been in that informed consent.
I don't have access to that document, but it was the responsibility of the clinical trial site coordinators or investigators to inform patients in the trial. I can't speak to how that may have been transmitted to the military personnel who were involved in the trial.